CLINICAL REVIEW SERVICES

  • Prospective: This review evaluates new prescriptions looking at drug-disease contraindications, drug-allergy interactions and therapeutic interchange. The DUR is conducted prior to the use of the medication to assure the proper application of drug to injury.

  • Concurrent: Applies the same analysis methodology to the ongoing drug profile being dispensed, especially for any adverse or non-positive results or benefits.  Appropriate during hospital stays, Post-Acute care settings, and long term home care.  

  • Retrospective: Evaluates medications that the patient has already been prescribed and started therapy. Includes long term financial analysis with life expectancy and drug cost inflation metrics.
  • PHARMD TO PEER CONSULT

    PharmD will consult with the treating physician to offer their expertise in drug regimen planning and associated risk. They will discuss recommendations, weaning and appropriate treatment guidelines.

    FORMULARY REVIEWS

    Doctors of Pharmacy will evaluate the individual state formularies and make recommendations on medications prescribed that are outside the formulary.

    TOXICOLOGY/DRUG TESTING REVIEWS

    Evaluates the toxicology results to determine whether it is in range with prescribing patterns and fill history. PharmD’s will analyze the findings in a brief summary report.

    DISPENSE-AS-WRITTEN REVIEWS

    We provide a neutral review outlet and evaluate the medical records to determine necessity of DAW1.

    PRE-INDEPENDENT EVALUATION REVIEWS (IME)

    Injured workers' medication regimen is evaluated and applied to the guidelines prior to the patient’s IME appointment. The PharmD streamlines the medication profile for the evaluating IME doctor. 

    DUR AND PEER REVIEW

    Retrospective DUR with an additional Peer Review by a Medical Doctor.

    COMPOUNDING REVIEWS

    Prospective evaluation for medical necessity.

    PRE-MSA DUR

    Recommended at least 6 months prior to filing with CMS.  This allows for potential changes in the treatment plan prior to submission. Evaluates long term financial exposure of medications and suggest alternatives with cost benefit.